Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7

PHASE3CompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

April 21, 2020

Study Completion Date

September 28, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

Tralokinumab

Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.

OTHER

Placebo

Placebo contains the same excipients in the same concentration only lacking tralokinumab.

Trial Locations (74)

1090

Leo Pharma Investigationel Site, Brussels

1200

Leo Pharma Investigationel Site, Brussels

2650

Leo Pharma Investigationel Site, Edegem

3000

Leo Pharma Investigationel Site, Leuven

4000

Leo Pharma Investigationel Site, Liège

6280

Leo Pharma Investigationel Site, Loverval

8500

Leo Pharma Investigationel Site, Kortrijk

9000

Leo Pharma Investigationel Site, Ghent

9990

Leo Pharma Investigationel Site, Maldegem

11000

Leo Pharma Investigationel Site, Prague

14004

Leo Pharma Investigationel Site, Córdoba

15006

Leo Pharma Investigationel Site, Prague

18014

Leo Pharma Investigationel Site, Granada

24105

Leo Pharma Investigationel Site, Kiel

26000

Leo Pharma Investigationel Site, Valence

28006

Leo Pharma Investigationel Site, Madrid

28046

Leo Pharma Investigationel Site, Madrid

28942

Leo Pharma Investigationel Site, Madrid

30159

Leo Pharma Investigationel Site, Hanover

31008

Leo Pharma Investigationel Site, Pamplona

36001

Leo Pharma Investigationel Site, Karlovy Vary

38000

Leo Pharma Investigationel Site, Grenoble

41007

Leo Pharma Investigationel Site, Seville

48013

Leo Pharma Investigationel Site, Bilbao

48249

Leo Pharma Investigationel Site, Dülmen

48455

Leo Pharma Investigationel Site, Bad Bentheim

49074

Leo Pharma Investigationel Site, Osnabrück

52074

Leo Pharma Investigationel Site, Aachen

53002

Leo Pharma Investigationel Site, Pardubice

55128

Leo Pharma Investigationel Site, Mainz

56242

Leo Pharma Investigationel Site, Selters

60590

Leo Pharma Investigationel Site, Frankfurt

69495

Leo Pharma Investigationel Site, Pierre-Bénite

70852

Leo Pharma Investigationel Site, Ostrava

75010

Leo Pharma Investigationel Site, Paris

80337

Leo Pharma Investigationel Site, München

86150

Leo Pharma Investigationel Site, Augsburg

B-9000

Leo Pharma Investigationel Site, Ghent

B-4040

Leo Pharma Investigationel Site, Herstal

284 01

Leo Pharma Investigationel Site, Kutná Hora

120 00

Leo Pharma Investigationel Site, Prague

130 00

Leo Pharma Investigationel Site, Prague

180 81

Leo Pharma Investigationel Site, Prague

06202

Leo Pharma Investigationel Site, Nice

10117,

Leo Pharma Investigationel Site, Berlin

01307

Leo Pharma Investigationel Site, Dresden

06097

Leo Pharma Investigationel Site, Halle

07743

Leo Pharma Investigationel Site, Jena

15-375

Leo Pharma Investigationel Site, Bialystok

32-700

Leo Pharma Investigationel Site, Bochnia

85-094

Leo Pharma Investigationel Site, Bydgoszcz

80-546

Leo Pharma Investigationel Site, Gdansk

30-149

Leo Pharma Investigationel Site, Krakow

31-530

Leo Pharma Investigationel Site, Krakow

31-559

Leo Pharma Investigationel Site, Krakow

90-242

Leo Pharma Investigationel Site, Lodz

90-752

Leo Pharma Investigationel Site, Lodz

20-081

Leo Pharma Investigationel Site, Lublin

60-369

Leo Pharma Investigationel Site, Poznan

35-312

Leo Pharma Investigationel Site, Rzeszów

01-817

Leo Pharma Investigationel Site, Warsaw

02-625

Leo Pharma Investigationel Site, Warsaw

02-953

Leo Pharma Investigationel Site, Warsaw

51-685

Leo Pharma Investigationel Site, Wroclaw

03010

Leo Pharma Investigationel Site, Alicante

08036

Leo Pharma Investigationel Site, Barcelona

08041

Leo Pharma Investigationel Site, Barcelona

08907

Leo Pharma Investigationel Site, Barcelona

BD5 0NA

Leo Pharma Investigationel Site, Bradford

HU16 5JQ

Leo Pharma Investigationel Site, Cottingham

KY2 5AH

Leo Pharma Investigationel Site, Kirkcaldy

E11 1NR

Leo Pharma Investigationel Site, London

SO16 6YD

Leo Pharma Investigationel Site, Southampton

WF1 4DG

Leo Pharma Investigationel Site, Wakefield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT03761537 - Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 | Biotech Hunter | Biotech Hunter